Boehringer Ingelheim has launched a cat-specific presentation of Metacam Injection combined with a new indication which permits the company's existing oral suspension (0.5mg/ml meloxicam) to be used for up to four follow-on days.
The company says this will give veterinary surgeons increased flexibility for managing feline post-operative pain, and that the new Metacam 2mg/ml Injection helps accurate dosing. Used at the recommended dose rate of 0.2mg/kg, the injection can be followed by Metacam 0.5mg/ml Oral Suspension to provide up to five days of analgesia following surgical procedures in cats. The licensed claims for Metacam 5mg/ml Injection for dogs and cats have not changed.
Boehringer added that Metacam is now the only brand which enables vets to offer their feline patients several days of post-operative analgesia, as well as being approved for long-term use for chronic musculoskeletal disease.
Claire Fowler, Boehringer Ingelheim's companion animal marketing manager, says that the new presentation and indication are significant developments in feline post-operative pain management: "Around half of all dogs undergoing surgery receive an injectable NSAID followed by a follow-on oral NSAID. In cats this figure is around 22%, yet there is no evidence to suggest that pain perception in cats should be any different to that of dogs".
Whilst you're here, take a moment to see our latest job opportunities for vets.
Veterinary Surgeon Jobs in England | Scotland | Wales | Ireland | Worldwide and
Veterinary Locums |
Follow VS Jobs on Facebook | Linkedin | Twitter | Contact
Click here to learn more about display and email advertising on VetSurgeon.org
Veterinary Forums | Veterinary News | Veterinary CPD | Veterinary Galleries
Veterinary Anaesthesia | Veterinary Cardiology | Veterinary Dentistry | Veterinary Dermatology | Diagnostic Imaging | Veterinary Medicine | Veterinary Neurology | Veterinary Oncology | Veterinary Surgery